An Open, Dose Escalation, Single Dose Study to Assess Tolerance and Pharmacokinetics of T0001 in Healthy Adult Chinese Volunteers

Trial Profile

An Open, Dose Escalation, Single Dose Study to Assess Tolerance and Pharmacokinetics of T0001 in Healthy Adult Chinese Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Jun 2017

At a glance

  • Drugs Hitanercept (Primary)
  • Indications Rheumatic disorders
  • Focus Adverse reactions; First in man
  • Sponsors Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
  • Most Recent Events

    • 12 Jun 2017 Results published in the European Journal of Clinical Pharmacology
    • 08 Jun 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 18 Nov 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top